Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

2026-02-12 - 05:38

SHANGHAI, Feb. 12, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase 2 proof-of-concept (PoC)